MDS Completes Sale of Late-Stage Pharma Services Group

MDS announced its plans to sell the business to INC for $50 million in early June as part of a broader strategy to focus the MDS Pharma Services business on services for early-stage discovery through Phase IIa, where it said it holds a "top-three" position in the market.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.